RedHill Biopharma Ltd. (RDHL)
NASDAQ: RDHL · Real-Time Price · USD
1.085
-0.005 (-0.46%)
At close: May 1, 2026, 4:00 PM EDT
1.080
-0.005 (-0.46%)
After-hours: May 1, 2026, 7:40 PM EDT
RedHill Biopharma Revenue
In the year 2025, RedHill Biopharma had annual revenue of $286.00K. RedHill Biopharma had revenue of $-3.79M in the half year ending December 31, 2025.
Revenue (ttm)
$286.00K
Revenue Growth
-95.13%
P/S Ratio
19.40
Revenue / Employee
$8,171
Employees
35
Market Cap
5.55M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 286.00K | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | 61.80M | -23.96M | -27.94% |
| Dec 31, 2021 | 85.76M | 21.40M | 33.25% |
| Dec 31, 2020 | 64.36M | 58.07M | 923.03% |
| Dec 31, 2019 | 6.29M | -2.07M | -24.75% |
| Dec 31, 2018 | 8.36M | 4.35M | 108.63% |
| Dec 31, 2017 | 4.01M | 3.91M | 3,867.33% |
| Dec 31, 2016 | 101.00K | 98.00K | 3,266.67% |
| Dec 31, 2015 | 3.00K | -7.01M | -99.96% |
| Dec 31, 2014 | 7.01M | 7.00M | 58,350.00% |
| Dec 31, 2013 | 12.00K | -4.00K | -25.00% |
| Dec 31, 2012 | 16.00K | -7.00K | -30.43% |
| Dec 31, 2011 | 23.00K | - | - |
| Dec 31, 2010 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Biofrontera | 41.71M |
| IM Cannabis | 39.92M |
| Sunshine Biopharma | 36.31M |
| cbdMD | 19.09M |
| Universe Pharmaceuticals INC | 17.86M |
| Sonoma Pharmaceuticals | 17.72M |
| InMed Pharmaceuticals | 4.51M |
| China SXT Pharmaceuticals | 1.54M |
RDHL News
- 3 days ago - RedHill's RHB-204 Demonstrates Comparable MAP Killing Efficacy to RHB-104 - Important Step in RHB-204 Development for MAP-related Crohn's Disease - PRNewsWire
- 6 days ago - RedHill Biopharma Announces Full-Year 2025 Financial Results and Operational Highlights - PRNewsWire
- 11 days ago - RedHill's Opaganib Enhances Efficacy of Neuroblastoma Chemo Combination and Augment Anti-Tumor Immunity in Triple-Negative Breast Cancer in Preclinical Studies - New Data Presented at AACR 2026 - PRNewsWire
- 2 months ago - Joint U.S. Commercialization of RedHill's Talicia® Commences - PRNewsWire
- 4 months ago - What's Going On With Redhill Biopharma Stock On Tuesday? - Benzinga
- 4 months ago - RedHill's RHB-102 Progresses in Multiple GI Indications Including GLP-1 Therapy-Related GI Side Effects - PRNewsWire
- 4 months ago - RedHill Biopharma's Positive Opaganib Results Indicate Reduction in Venetoclax Resistant Cells - PRNewsWire
- 5 months ago - RedHill Biopharma Successfully Regains Compliance with Nasdaq Stockholders' Equity Requirement - PRNewsWire